2. Search Result
Search Result
Results for "

iPSC-derived cardiomyocytes

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124815
    CP-312

    		Reactive Oxygen Species (ROS) Others
    CP-312 is a potent Heme Oxygenase-1 (HO-1) inducer. CP-312 protects hiPSC-CM viability by targeting the antioxidant response network through induction of HMOX1 expression. CP-312 protects human iPSC-derived cardiomyocytes from oxidative stress .
    CP-312
  • HY-175984
    S1P1 agonist 7

    		LPL Receptor Inflammation/Immunology
    S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC50(G‑protein) = 12.7 nM and EC50(β‑arrestin) = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research .
    S1P1 agonist 7
  • HY-124815R
    CP-312 (Standard)

    		Reactive Oxygen Species (ROS) Others
    CP-312 (Standard) is the analytical standard of CP-312. This product is intended for research and analytical applications. CP-312 is a potent Heme Oxygenase-1 (HO-1) inducer. CP-312 protects hiPSC-CM viability by targeting the antioxidant response network through induction of HMOX1 expression. CP-312 protects human iPSC-derived cardiomyocytes from oxidative stress .
    CP-312 (Standard)
  • HY-W207224
    F1386-0303

    		MAP4K Cardiovascular Disease Inflammation/Immunology
    F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
    F1386-0303

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: